当前位置： SCI文献检索 > Journal of the International AIDS Society期刊下所有文献 > Transmitted drug resistance to rilpivirine among antiretroviral-naïve patients living with HIV from northern Poland.

Transmitted drug resistance to rilpivirine among antiretroviral-naïve patients living with HIV from northern Poland.

Abstract：

INTRODUCTION:Rilpivirine (RPV) is a second-generation non-nucleoside reverse transcriptase inhibitor (NNRTI) that was recently approved for the treatment of antiretroviral-naïve individuals with HIV-1 viral load of <100,000 copies/ml. As transmission of the drug resistance mutations to this NNRTI may affect treatment outcomes, the frequency of primary, RPV-associated drug resistance mutations was assessed in this study. METHODS:For the study, 244 viral genome sequences from antiretroviral-naïve individuals were obtained by bulk sequencing. RPV-associated mutations were divided into RPV resistance mutations (K101E/P, E138A/G/K/Q/R, V179L, Y181C/I/V, Y188L, H221Y, F227C and M230I/L) according to the International AIDS Society-USA (IAS-USA) mutation list and variants potentially affecting RPV susceptibility (L100I, K101H/T, E138S, V179F/D/G/T, G190A/E/S, F227L and M230V) based on the in vitro and in vivo data. RESULTS:IAS-USA RPV drug resistance mutations were found in 5.3% sequences, with E138A and E138G being the most common (3.7 and 0.8%, respectively), followed by K101E (0.4%) and Y181C (0.4%), with no significant differences in the frequency between subtype B and non-B clades. Mutations potentially reducing RPV susceptibility were found in 2.5% of sequences, and they included V179D (1.6%) and G190A (0.8%), with equal distribution among non-B (n=2, 2.5%) and subtype B (n=4, 2.5%) clades. Clustering of RPV mutations was infrequent. CONCLUSIONS:Prevalence of RPV-associated drug resistance mutations was low in the analysed sample and did not vary across the subtypes. The frequency of variants with potential influence on RPV susceptibility was similar among non-B variants if compared to B clades. Transmitted drug resistance to RPV is uncommon, which makes this a good option for the treatment of ARV-naïve patients; however, genotype resistance testing should remain compulsory before starting an RPV-based regimen.

journal_name

J Int AIDS Soc

journal_title

Journal of the International AIDS Society

authors

Parczewski M,Urbańska A,Maciejewska K,Witak-Jȩdra M,Leszczyszyn-Pynka M

doi

10.7448/IAS.17.1.18929

subject

Has Abstract

pub_date

2014-04-17 00:00:00

pages

18929

issn

1758-2652

pii

18929

journal_volume

pub_type

杂志文章

在线工具

Transmitted drug resistance to rilpivirine among antiretroviral-naïve patients living with HIV from northern Poland.